APM
ITOS

Avidity Partners Management’s iTeos Therapeutics ITOS Stock Holding History

Avidity Partners Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-92,574
Closed -$3.13M – 108
2020
Q4 		$3.13M Sell
92,574
-237,426
-72% -$6.29M 0.1% 87
2020
Q3 		$8.14M Buy
+330,000
New +$8.88M 0.38% 50

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Avidity Partners Management's ITOS Position: Q1 2021 in Review

Avidity Partners Management sold out of iTeos Therapeutics (ITOS) in Q1 2021, closing a stake of 92,574 shares — an estimated $3.13M sold.

Avidity Partners Management first reported a position in ITOS in Q3 2020 and held it in 2 quarters. The position peaked at $8.14M in Q3 2020. 81 funds tracked by Wall St. Rank hold ITOS as of Q1 2021.

  • Avidity Partners Management reported no remaining iTeos Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 92,574 iTeos Therapeutics shares in Q1 2021, an estimated $3.13M.
  • Avidity Partners Management first reported a position in iTeos Therapeutics in Q3 2020 and held it in 2 quarters.
  • Avidity Partners Management's iTeos Therapeutics position peaked at $8.14M in Q3 2020.
  • 81 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.